Drug intelligence / Profile preview

Eyeon Protect

Development stage: Unknown
Lead developer: Calm Water Therapeutics
Modality: Small Molecules
Administration: Ophthalmic

Overview

Eyeon Protect is a glycerin-based ophthalmic solution developed by Calm Water Therapeutics for the treatment of keratoconjunctivitis sicca, commonly known as dry eye syndrome. It functions as an ophthalmic demulcent and humectant, providing a protective film over the ocular surface and promoting moisture retention to stabilize the tear film. By increasing the residence time of moisture on the eye and reducing evaporation, it alleviates symptoms such as irritation, redness, and discomfort. Clinical studies have compared its performance in tear film stability against established lubricant eye drops containing polyethylene glycol and propylene glycol to evaluate its efficacy in managing dry eye disease.

Brand names: Eyeon Protect
Other names: Glycerin ophthalmic solution

Beyond the preview

Go deeper on Eyeon Protect.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyeon Protect.

Explore the full profile